The FDA has approved Nexterone (amiodarone HCl, from Prism Pharmaceuticals) Injection, a cosolvent-free formulation of Amiodarone IV. The removal of the cosolvents, polysorbate 80 and benzyl alcohol, overcomes the limitations with the product administration, specifically the compatibility and stability with plastics and ionic infusion fluids. Additionally, Nexterone does not carry the specific warning about the risk of fatal gasping syndrome in newborn infants because it does not contain benzyl alcohol.
Nexterone is indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.
For more information call (610) 265-7710 or visit www.prismpharma.com.